Histologically proven gastritis is a very common disease with which Campylobacter pyloridis is associated in most cases (9, 13, 15) . The other arguments for the pathogenicity of this bacterial species are (i) an increase in antibody levels against C. pyloridis antigens in patients with C. pyloridis (2, 6, 11) and (ii) the development of the disease after an experimental inoculation with C. pyloridis of a volunteer (10) . Further proof of this association could be generated from a clinical trial with antibiotics versus placebo. At present, a better knowledge of the spectrum of susceptibility of this bacterial species is needed. As a result of this type of work, a more adapted selective medium could also be developed.
In this study we tested the susceptibility of 50 strains of C. pyloridis to 20 antimicrobial agents representing the different families of antibiotics. The MICs were determined by the standard dilution technique in solid medium. The following antibiotics were tested: penicillin G (Specia RP, Paris, France), ampicillin and kanamycin (Bristol, Paris, France), clavulanic acid, amoxicillin plus clavulanic acid (BeechamSevigne, Paris, France), cephalothin, tobramycin, and vancomycin (Eli Lilly, Saint Cloud, France), cefotaxime, chloramphenicol, erythromycin, and streptomycin (Roussel-UCLAF, Paris, France), cefsulodin (Ciba-Geigy, Rueil Malmaison, France), gentamicin (Unilabo, Levallois, France), josamycin (Pharmuka, Gennevilliers, France), lincomycin (Upjohn, Paris, France), oxytetracycline hydrochloride (Pfizer, Orsay, France), rifampin (Le Petit, Neuilly sur Seine, France), pefloxacin, and colistin (Roger Bellon, Neuilly sur Seine, France). The plates were prepared the day before testing and stored at 4°C.
The strains were isolated from patients attending an endoscopic clinic in Bordeaux and presenting upper gastrointestinal symptoms (25 had ulcers and 25 had nonulcerous dyspepsia with histological lesions of gastritis). The gastric antrum biopsies were inoculated onto chocolate agar and brucella agar supplemented with 10% sheep blood and antibiotics as described by Skirrow (17) . After an incubation period of 3 to 6 days at 370C in a microaerobic atmosphere, the bacteria were identified as C. pyloridis by morphology, positive oxidase, catalase, urease, and -y-glutamyl transferase tests. Sixteen of these strains were studied more extensively (16) . All the strains were adapted to growth in vitro and were passaged five times. They were maintained frozen at -700C. * (14) . Three antibiotics were identical and gave similar results. C. pyloridis resembles the C. jejuni-C. coli group in that it was susceptible to clavulanic acid (1). These three bacterial species had a comparable spectrum of susceptibility to chloramphenicol, tetracycline, vancomycin, colistin, and the aminoglycosides, except for a single strain in the C. jejuni-C. coli group (8) . There was also a similarity in the susceptibility patterns for erythromycin, jogamycin, and lincomycin (3) . Differences were found with ampicillin (40% resistance in the C. jejini-C. coli group), cephalothin (100% resistance), and rifampin (100% resistance). However, rifampin is known to be active against "C. cinaedi' and "C.Jfnnelliae" (4) .
Since strains of this bacterial species are resistant to nalidixic acid (13), we tested a new quinolone which has been proposed to separate nalidixic acid-resistant strains (18) . Pefloxacin showed lower activity than ciprofloxacin (14) tested in another study.
A selective medium is necessary to isolate C. pyloridis from biopsy specimens because of contamination, particularly by Streptococcus sp. and Pseudomonas aeruiginosa. The selective medium which is currently used contains (per milliliter) vancomycin (5 ,ug), trimethroprim (2.5 ,ug), colistin (5 ,ug), and, in some cases, nalidixic acid (10 ,ug) (5, 12) . This medium is unsuitable for the isolation of C. pyloridis since many strains are inhibited by colistin or nalidixic acid or both. In addition, overgrowth of P. aeruiginosa occurred before the optimum incubation time for the C. pyloridis. We have tested cefsulodin in an attempt to find an alternative to We did not find strains of C. pyloridis, in particular, resistant to the antibiotics (macrolides, tetracyclines, and ampicillin) for treating gastritis which could be used in control studies to resolve the question of the pathogenicity of these bacteria. However, all the strains must be screened systematically if a resistant strain is to be found.
